Sebastian Gensior

Introduction – Deals as the New Discovery Platform biotech companies today often make headlines not for proven drugs, but for deals – multi-million (or billion) dollar partnerships that monetize future possibilities. These startups have cutting-edge discovery platforms (AI-driven design, novel biology engines, etc.), yet few validated products. Instead of

Biopharma royalty deals are financial transactions where an investor purchases the right to receive future royalty payments from a drug or therapy, in exchange for an upfront payment (and sometimes milestone payments) to the selling party. These arrangements have become an important alternative financing mechanism in the pharmaceutical and biotech

For large pharmaceutical firms, the week’s deals underscored a willingness to spend on promising science – especially to hedge against looming patent cliffs. Japan’s Otsuka Pharmaceuticals, for instance, struck a $613 million licensing deal with Sweden’s Cantargia to snag rights to an IL1RAP-targeting antibody for inflammatory diseases.

The biotech industry’s appetite for artificial intelligence has grown insatiable. From AI-driven drug discovery and protein folding to generative chemistry and medical imaging, cutting-edge models are churning through terabytes of data in pursuit of new medicines and insights. These tasks – folding a protein with AlphaFold, screening billions

In June 2025, NATO quietly co‑led a US $35 million Series A funding round for Portal Biotech, a UK startup developing portable, AI‑enabled biological sensors capable of single-molecule protein sequencing in the field. It was NATO’s first formally disclosed biotech investment—proof that microbes, not missiles,

Artificial intelligence (AI) has permeated the pharmaceutical industry with promises to transform everything from drug discovery to clinical trials. By 2025, a clearer picture has emerged of what AI is actually delivering in pharma – and what core challenges remain. This comprehensive review takes a critical, look at how AI is

The second half of 2025 is poised to deliver a wave of critical clinical trial readouts across the biopharmaceutical industry. From potential blockbuster obesity drugs to cutting-edge gene therapies and vaccines, dozens of late-stage studies around the world will report data that could reshape treatment paradigms and financial

Alzheimer’s disease, the most common form of dementia, poses one of the greatest challenges in modern medicine. Every year, about 10 million people around the world are diagnosed with dementia, and over 55 million are currently living with it. As populations age, those numbers are projected to rise to

It begins, as all good policies do, with a peer-reviewed article. A study from 2013 estimates the cost of a hospital stay for rheumatoid arthritis. The figure is well-argued, methodologically neat, and printed in an impeccable journal. The number is then cited in a 2017 HTA submission. That

The first half of 2025 has seen a wave of new venture capital (VC) and private equity (PE) funds dedicated to pharmaceuticals and biotech, even as the broader funding climate remains cautious. Investors are selectively raising and deploying billions into life sciences – from mega-funds amassing war chests for drug